Investor Relations

HCW Biologics Inc. (Nasdaq: HCWB) is a clinical stage biopharmaceutical company developing first-in-class immunotherapies to revolutionize the treatments for autoimmune diseases, cancer and senescence-associated dysplasia.

We have created novel fusion compounds that represent a new class of drugs that we believe have the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. Among other things, we have begun commercialization of certain commercial-ready proprietary compounds for use as reagents in the production of immunotherapeutics for the treatment of infectious diseases and cancer. We hope our products improve patients’ healthspan as well as their quality of life, and possibly extend longevity.

HCW Biologics Inc.(NasdaqGM:HCWB) added to S&P TMI Index